TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2022 Financial Results and Business Update
TG Therapeutics will host a conference call on February 28, 2023, at 8:30 AM ET to discuss its 2022 fourth-quarter and year-end results and provide a business outlook for 2023. The call will be led by Michael S. Weiss, the company’s Chairman and CEO. Participants can join the call by dialing 1-877-407-8029 within the U.S. or 1-201-689-8029 from outside the U.S.
A live webcast will be available on TG Therapeutics' website, and a recording will be accessible for 30 days post-call. The company focuses on developing treatments for B-cell diseases and has received FDA approval for BRIUMVI™ for specific multiple sclerosis conditions.
- Upcoming conference call to discuss financial results and business outlook could provide positive insights for investors.
- FDA approval of BRIUMVI™ enhances product portfolio and market position.
- None.
Conference call to be held Tuesday, February 28, 2023 at 8:30 AM ET
NEW YORK, Feb. 24, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Tuesday, February 28, 2023 at 8:30 AM ET to discuss results for the fourth quarter and year-end 2022 and provide a business outlook for 2023. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call.
In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Fourth Quarter and Year End 2021 Update Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com. An audio recording of the conference call will also be available for replay at www.tgtherapeutics.com, for a period of 30 days after the call.
TG Therapeutics will announce its financial results for this period in a press release to be issued prior to the call.
ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has received approval from the U.S. FDA for BRIUMVI™ (ublituximab-xiiy), for the treatment of adult patients with relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. For more information, visit www.tgtherapeutics.com, and follow us on Twitter @TGTherapeutics and on LinkedIn.
CONTACT:
Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4
Media Relations:
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6
FAQ
When is the TG Therapeutics conference call?
Who will lead the TG Therapeutics conference call?
What will be discussed during the TG Therapeutics conference call?
How can I participate in the TG Therapeutics conference call?
Where can I find the webcast of the TG Therapeutics conference call?
